{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:18:04Z","timestamp":1707524284883},"reference-count":14,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2021,6,14]]},"DOI":"10.7759\/cureus.15637","type":"journal-article","created":{"date-parts":[[2021,6,14]],"date-time":"2021-06-14T11:37:00Z","timestamp":1623670620000},"source":"Crossref","is-referenced-by-count":0,"title":["Atezolizumab, a PD-L1 Inhibitor: An Association of Bleeding Gastric Ulcer With Its Use"],"prefix":"10.7759","author":[{"given":"Anusha","family":"Bapatla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tooba","family":"Tariq","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam Bilal","family":"Haider","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bashar","family":"Mohamad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.20524\/aog.2020.0552","article-title":"Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis","volume":"34","author":"Shieh C","year":"2021","unstructured":"Shieh C, Chalikonda D, Block P, Shinn B, Kistler CA. Gastrointestinal toxicities of immune checkpoint inhibitors: a multicenter retrospective analysis. Ann Gastroenterol. 2021, 34:46-52. 10.20524\/aog.2020.0552","journal-title":"Ann Gastroenterol"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1093\/rheumatology\/kez418","article-title":"Toxicities associated with checkpoint inhibitors-an overview","volume":"58","author":"Spiers L","year":"2019","unstructured":"Spiers L, Coupe N, Payne M. Toxicities associated with checkpoint inhibitors-an overview. Rheumatology (Oxford). 2019, 58:vii7-vii16. 10.1093\/rheumatology\/kez418","journal-title":"Rheumatology (Oxford)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1038\/s41424-018-0049-9","article-title":"Immune checkpoint inhibitor-associated colitis and hepatitis","volume":"9","author":"Reddy HG","year":"2018","unstructured":"Reddy HG, Schneider BJ, Tai AW. Immune checkpoint inhibitor-associated colitis and hepatitis. Clin Transl Gastroenterol. 2018, 9:180. 10.1038\/s41424-018-0049-9","journal-title":"Clin Transl Gastroenterol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1177\/1756284819884196","article-title":"Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management","volume":"12","author":"Shivaji UN","year":"2019","unstructured":"Shivaji UN, Jeffery L, Gui X, et al.. Immune checkpoint inhibitor-associated gastrointestinal and hepatic adverse events and their management. Therap Adv Gastroenterol. 2019, 12:1756284819884196. 10.1177\/1756284819884196","journal-title":"Therap Adv Gastroenterol"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.cdtm.2017.12.001","article-title":"Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors","volume":"4","author":"Wang ZH","year":"2018","unstructured":"Wang ZH, Shen L. Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. Chronic Dis Transl Med. 2018, 4:1-7. 10.1016\/j.cdtm.2017.12.001","journal-title":"Chronic Dis Transl Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v24.i48.5433","article-title":"Checkpoint inhibitors: what gastroenterologists need to know","volume":"24","author":"Ahmed M","year":"2018","unstructured":"Ahmed M. Checkpoint inhibitors: what gastroenterologists need to know. World J Gastroenterol. 2018, 24:5433-8. 10.3748\/wjg.v24.i48.5433","journal-title":"World J Gastroenterol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2019.1594356","article-title":"Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors","volume":"54","author":"Tang T","year":"2019","unstructured":"Tang T, Abu-Sbeih H, Luo W, et al.. Upper gastrointestinal symptoms and associated endoscopic and histological features in patients receiving immune checkpoint inhibitors. Scand J Gastroenterol. 2019, 54:538-45. 10.1080\/00365521.2019.1594356","journal-title":"Scand J Gastroenterol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2018-BSGAbstracts.131","article-title":"PTU-009\u2005Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea","volume":"67","author":"Fazal MW","year":"2018","unstructured":"Fazal MW, Spain L, Ibraheim H, et al.. PTU-009\u2005Upper gastrointestinal inflammation in patients with immune-checkpoint inhibitor induced diarrhoea. Gut. 2018, 67:A66-7. 10.1136\/gutjnl-2018-BSGAbstracts.131","journal-title":"Gut"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.5858\/arpa.2019-0700-OA","article-title":"Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, Helicobacter pylori gastritis and celiac disease","volume":"145","author":"Irshaid L","year":"2021","unstructured":"Irshaid L, Robert ME, Zhang X. Immune checkpoint inhibitor-induced upper gastrointestinal tract inflammation shows morphologic similarities to, but is immunologically distinct from, Helicobacter pylori gastritis and celiac disease. Arch Pathol Lab Med. 2021, 145:191-200. 10.5858\/arpa.2019-0700-OA","journal-title":"Arch Pathol Lab Med"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz446.002","article-title":"IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC)","volume":"30","author":"Cheng A-L","year":"2019","unstructured":"Cheng A-L, Qin S, Ikeda M, et al.. IMbrave150: Efficacy and safety results from a ph III study evaluating atezolizumab (atezo) 1 bevacizumab (bev) vs sorafenib (Sor) as first treatment (tx) for patients (pts) with unresectable hepatocellular carcinoma (HCC). Annals of Oncology. 2019, 30:IX186-7. 10.1093\/annonc\/mdz446.002","journal-title":"Annals of Oncology"},{"key":"ref11","doi-asserted-by":"crossref","DOI":"10.14309\/00000434-201810001-01906","article-title":"Proximal gastrointestinal ulcerations: a potential complication of atezolizumab therapy?","volume":"113","author":"Swei E","year":"2018","unstructured":"Swei E, Lin A, Chang BW, Bissonnette M, Alpert L, Serritella A. Proximal gastrointestinal ulcerations: a potential complication of atezolizumab therapy?. Am J Gastroenterol. 2018, 113:1082.","journal-title":"Am J Gastroenterol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1007\/s12328-020-01218-0","article-title":"A rare case of immunotherapy-induced cholangitis and gastritis","volume":"13","author":"Fujii M","year":"2020","unstructured":"Fujii M, Ozato T, Mizukawa S, et al.. A rare case of immunotherapy-induced cholangitis and gastritis. Clin J Gastroenterol. 2020, 13:1083-90. 10.1007\/s12328-020-01218-0","journal-title":"Clin J Gastroenterol"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1159\/000494569","article-title":"Management of gastrointestinal toxicity from immune checkpoint inhibitor","volume":"26","author":"Rocha M","year":"2019","unstructured":"Rocha M, Correia de Sousa J, Salgado M, Ara\u00fajo A, Pedroto I. Management of gastrointestinal toxicity from immune checkpoint inhibitor. GE Port J Gastroenterol. 2019, 26:268-74. 10.1159\/000494569","journal-title":"GE Port J Gastroenterol"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.77.6385","article-title":"Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline","volume":"36","author":"Brahmer JR","year":"2018","unstructured":"Brahmer JR, Lacchetti C, Schneider BJ, et al.. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2018, 36:1714-68. 10.1200\/JCO.2017.77.6385","journal-title":"J Clin Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/61564-atezolizumab-a-pd-l1-inhibitor-an-association-of-bleeding-gastric-ulcer-with-its-use","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:24:35Z","timestamp":1707506675000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/61564-atezolizumab-a-pd-l1-inhibitor-an-association-of-bleeding-gastric-ulcer-with-its-use"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,14]]},"references-count":14,"URL":"https:\/\/doi.org\/10.7759\/cureus.15637","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2021,6,14]]}}}